BioCryst Pharmaceuticals BCRX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from BioCryst Pharmaceuticals’s reported figures.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's free cash flow?
- BioCryst Pharmaceuticals (BCRX) reported free cash flow of -$62.19M in Q1 2026.
- How has BioCryst Pharmaceuticals's free cash flow changed year-over-year?
- BioCryst Pharmaceuticals's free cash flow decreased by 124.9% year-over-year, from -$27.66M to -$62.19M.
- What is the long-term trend for BioCryst Pharmaceuticals's free cash flow?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's free cash flow has grown at a 33.6% compound annual growth rate (CAGR), from -$144.54M to $344.9M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.